At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Alemtuzumab and rituximabdrug
Likely dose
Alemtuzumab and rituximab 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combination of Alemtuzumab (Anti-CD52) and Rituximab (Anti-CD20) at Low-doses in Chronic Graft Versus Host Disease Treatment After First-line Therapy Failure.
In Brief
A clinical study evaluating Alemtuzumab and rituximab for Graft vs Host Disease. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether low-doses alemtuzumab and rituximab combination are effective in the treatment of chronic graft-versus-host disease (GVHD) after first-line therapy failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft vs Host Disease
CountriesMexico
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedJan 2010
Primary CompletionOct 2011
Study CompletionJan 2012
TodayJul 2026
First PostedJan 5, 2010
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.5 years ago
Interventions
Alemtuzumab and rituximabdrug
Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25